Dual-Targeting Multivalent Aptamer-Drug Hybrids for Synergistic Cancer Immunotherapy
synergize with PD-1 blockade to achieve durable tumor eradication and long-term protection. These findings establish multivalent aptamer-drug hybrids as a versatile platform for multitarget, multipayload precision therapeutics and highlight their potential for next-generation TDC design.
Authors
- Wangbo Qu (ORCID: https://orcid.org/0000-0001-8756-4412)
- Tao Fu (ORCID: https://orcid.org/0000-0003-1783-2631)
- Xinni Liu (ORCID: https://orcid.org/0000-0002-3970-7631)
- Keli An
- Anna S. Kichkailo (ORCID: https://orcid.org/0000-0003-1054-4629)
- Yanlin Du (ORCID: https://orcid.org/0000-0001-8268-4925)
- Zheng Wang (ORCID: https://orcid.org/0000-0003-4873-505X)
- Chunyan Fan (ORCID: https://orcid.org/0000-0001-6673-6238)
- Yuxin Zeng (ORCID: https://orcid.org/0009-0008-6085-8873)
- Hongli Chi (ORCID: https://orcid.org/0000-0002-2455-8151)
- Xinru Lv
- Wei Lv
- Sining Zhao
- Ming Cheng
- Pengju Li
Institutions
- Tianjin University (CN)
- Chinese Academy of Sciences (CN)
- University of Macau (MO)
- Karolinska Institutet (SE)
- Krasnoyarsk Scientific Center (RU)
- Krasnoyarsk State Medical University (RU)
- Zhejiang Cancer Hospital (CN)
- Institute of Biophysics (BG)
- Institute of Molecular Biology and Biophysics (RU)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Journal of the American Chemical Society
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1021/jacs.5c21968
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Zhejiang Province